First Bank & Trust Grows Position in Pfizer Inc. (NYSE:PFE)

First Bank & Trust raised its position in Pfizer Inc. (NYSE:PFE) by 3.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,695 shares of the biopharmaceutical company’s stock after acquiring an additional 2,459 shares during the quarter. First Bank & Trust’s holdings in Pfizer were worth $2,248,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PFE. LGT Group Foundation raised its stake in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares in the last quarter. Creative Planning lifted its stake in Pfizer by 17.1% during the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock worth $52,692,000 after purchasing an additional 266,167 shares during the last quarter. ORG Partners LLC boosted its holdings in Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Pfizer by 10.3% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock worth $7,422,000 after purchasing an additional 23,928 shares in the last quarter. Finally, Everett Harris & Co. CA lifted its position in shares of Pfizer by 21.7% during the 3rd quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock worth $6,319,000 after buying an additional 38,870 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Citigroup initiated coverage on Pfizer in a research note on Friday. They set a “neutral” rating and a $30.00 price target on the stock. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Performance

NYSE:PFE traded down $0.19 during mid-day trading on Friday, reaching $28.45. The stock had a trading volume of 26,091,111 shares, compared to its average volume of 36,849,277. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The business has a 50 day simple moving average of $29.08 and a 200 day simple moving average of $28.50. The firm has a market capitalization of $161.22 billion, a price-to-earnings ratio of -61.85, a PEG ratio of 1.01 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.67 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.91%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.